Portal de Periódicos da CAPES

SARS‐CoV‐2 candidate vaccines ‐ composition, mechanisms of action and stages of clinical development

2020; Wiley; Volume: 76; Issue: 6 Linguagem: Inglês

10.1111/all.14714

1398-9995

Juan Rodríguez‐Coira, Milena Sokołowska,

Drug-Induced Adverse Reactions

AllergyVolume 76, Issue 6 p. 1922-1924 NEWS & VIEWS SARS-CoV-2 candidate vaccines - composition, mechanisms of action and stages of clinical development Juan Rodriguez-Coira, Juan Rodriguez-Coira orcid.org/0000-0003-0517-7078 Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland Instituto de Medicina Molecular Aplicada, Grupo Hospital Madrid, Universidad San Pablo-CEU, CEU Universities, Madrid, España Facultad de Farmacia, Centro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Madrid, EspañaSearch for more papers by this authorMilena Sokolowska, Corresponding Author Milena Sokolowska [email protected] orcid.org/0000-0001-9710-6685 Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland Christine Kühne - Center for Allergy Research and Education (CK-CARE, Davos, Switzerland Correspondence Milena Sokolowska, Head Immune Metabolism, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Herman-Burchard-Strasse 9, CH-7265 Davos-Wolfgang, Switzerland. Email: [email protected]Search for more papers by this author Juan Rodriguez-Coira, Juan Rodriguez-Coira orcid.org/0000-0003-0517-7078 Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland Instituto de Medicina Molecular Aplicada, Grupo Hospital Madrid, Universidad San Pablo-CEU, CEU Universities, Madrid, España Facultad de Farmacia, Centro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Madrid, EspañaSearch for more papers by this authorMilena Sokolowska, Corresponding Author Milena Sokolowska [email protected] orcid.org/0000-0001-9710-6685 Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland Christine Kühne - Center for Allergy Research and Education (CK-CARE, Davos, Switzerland Correspondence Milena Sokolowska, Head Immune Metabolism, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Herman-Burchard-Strasse 9, CH-7265 Davos-Wolfgang, Switzerland. Email: [email protected]Search for more papers by this author First published: 19 December 2020 https://doi.org/10.1111/all.14714Citations: 21 Funding information JRC is supported by a FPI of Universidad CEU San Pablo and SEMP from University of Zurich. MS is supported by the Swiss National Science Foundation grant nr 310030_189334/1. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Sokolowska M, Lukasik ZM, Agache I, et al. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020; 75(10): 2445-2476. 10.1111/all.14462 CASPubMedWeb of Science®Google Scholar 2 WHO. Draft Landscape of COVID-19 Candidate Vaccines. Accessed on 12th of December 2020. Geneva: WHO; 2020. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Google Scholar 3Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020; 586(7830): 516-527. 10.1038/s41586-020-2798-3 CASPubMedWeb of Science®Google Scholar 4Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014; 210(Suppl 1): S283-293. 10.1093/infdis/jiu295 PubMedWeb of Science®Google Scholar 5Sadoff J, Le Gars M, Shukarev G, et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial. medRxiv. 2020; 2020: 2023. Google Scholar 6Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395(10240): 1845-1854. 10.1016/S0140-6736(20)31208-3 CASPubMedWeb of Science®Google Scholar 7Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396(10255): 887-897. 10.1016/S0140-6736(20)31866-3 CASPubMedWeb of Science®Google Scholar 8Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249): 467-478. 10.1016/S0140-6736(20)31604-4 CASPubMedWeb of Science®Google Scholar 9Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20): 1920-1931. 10.1056/NEJMoa2022483 CASPubMedWeb of Science®Google Scholar Citing Literature Volume76, Issue6June 2021Pages 1922-1924 ReferencesRelatedInformation